Global Viral Vaccine Market Grows Steadily at a CAGR of 4.05%

Viral vaccines are designed to protect the organism against viral infections by stimulating the immune system to recognize and fight against that specific virus. A harmless version of the virus is introduced inside the host’s body, such as live attenuated, inactivated, or made from other viral components, such as proteins, to enhance the immune response. The immune system then recognizes the virus as foreign and produces antibodies that specifically target it. This process trains the immune system to respond more effectively if it encounters the actual virus in the future.

High prevalence rates of viral infectious diseases drive the global market

The growing global demand for viral vaccines is driven by the rising prevalence and incidence of viral diseases like COVID-19, influenza, hepatitis, and the emergence of new infections. For instance, in November 2024, the World Health Organization (WHO) reported that measles affected 10.3 million people worldwide.

In response, WHO, the Measles and Rubella Partnership and other global organizations ramped up immunization efforts, significantly lowering the death rate through vaccination. As the incidence of such diseases continues to increase, the demand for effective vaccines to curb their spread and safeguard populations grows, contributing to the continued expansion.

Expansion of mRNA vaccine technology creates tremendous opportunities

The viral vaccine market is experiencing a significant shift with the rapid advancement and expansion of mRNA vaccine technology, which offers speed, flexibility, and broad applicability across various diseases. This innovative approach is opening up new opportunities for the development of vaccines for a wide range of viral infections.

For example, in January 2023, Moderna announced that its mRNA-1345 vaccine, designed to protect against Respiratory Syncytial Virus (RSV), successfully met the primary efficacy endpoints in a Phase 3 trial involving older adults. This achievement demonstrates the potential of mRNA technology to address unmet medical needs.

As this technology evolves, it promises to revolutionize vaccine development and improve public health outcomes, creating new avenues for the global viral vaccines market.

North America remains the dominant market for the global viral vaccines market, particularly driven by the U.S. due to its advanced healthcare infrastructure, high vaccine demand, strong public healthcare initiatives, and the presence of key market players. The region’s faster-growing vaccination campaigns, such as Covid-19 and influenza, contribute significantly to the market share.

The U.S., being the home of the largest pharmaceutical companies, is developing new vaccine technologies, including m RNA vaccines and viral vector vaccines. Moreover, the Centers for Disease Control and Prevention U.S., a public health organization, plays an essential role in spreading the importance related to vaccination programs.

Key Highlights

• The global viral vaccines market size was valued at USD07 billion in 2024 and is projected to grow from USD 57.72 billion in 2025 to reach USD 79.27 billion by 2033, growing at a CAGR of 4.05% during the forecast period (2025-2033).
• Based on types, the global market is segmented intolive attenuated vaccines, inactivated vaccines, and sub-unit vaccines. The live attenuated segment is the largest revenue contributor.
• Based on consumer groups, the global viral vaccine market is segmented into pediatrics and adults. The pediatrics segment is the largest revenue contributor to the market.
• Based on disease indication, the global market is segmented into cancer, influenza, human papillomavirus, rotavirus, poliomyelitis, hepatitis, and others. The influenza segment is the largest revenue contributor.
• Based on the route of administration, the global viral vaccine market is segmented into parenteral and oral. The parenteral segment has the largest revenue contribution.
• North America is the highest shareholder in the global market.

Market Segments

1. By Types
   1. Live attenuated vaccines
   2. Inactivated vaccines
   3. Sub-Unit viral vaccines
2. By Consumer groups
   1. Pediatric
   2. Adults
3. By Disease Indication
   1. Cancer
   2. Influenza
   3. Human Papilloma Virus
   4. Rota Virus
   5. Poliomyelitis
   6. Hepatitis
   7. Others
4. By Route of Administration
   1. Parenteral
   2. Oral